(Q37189789)

18 August 2017

1 reference

title

Alternate delivery route for amifostine as a radio-/chemo-protecting agent (English)

1 reference

18 August 2017

1 reference

ChEBI release 2020-05-28

Natalie P Praetorius

1

1 reference

18 August 2017

Tarun K Mandal

series ordinal

2

1 reference

18 August 2017

publication date

1 July 2008

1 reference

Journal of Pharmacy and Pharmacology

18 August 2017

published in

1 reference

18 August 2017

volume

60

1 reference

18 August 2017

issue

7

1 reference

18 August 2017

page(s)

809-815

1 reference

Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.7.0001

Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.7.0001

A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.7.0001

Amifostine in the management of radiation-induced and chemo-induced mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.7.0001

New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.7.0001

Pharmacologic approaches to radiation protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.7.0001

Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.7.0001

A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.7.0001

Amifostine: the first selective-target and broad-spectrum radioprotector

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.7.0001

Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.7.0001

Oral delivery of spray dried PLGA/amifostine nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.7.0001

Radioprotection in mice following oral delivery of amifostine nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.7.0001

Radioprotection, pharmacokinetic and behavioural studies in mouse implanted with biodegradable drug (amifostine) pellets

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.60.7.0001

21 January 2018

Identifiers

DOI

10.1211/JPP.60.7.0001

1 reference

18 August 2017

1 reference